Improving glyburide solubility and dissolution by complexation with hydroxybutenyl-β-cyclodextrin

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 1, 2009, Pages 23-30

  Klein, Sandra ^a   Wempe, Michael F ^b,c   Zoeller, Thomas ^a   Buchanan, Norma L ^b   Lambert, Juanelle L ^b   Ramsey, Michael G ^b   Edgar, Kevin J ^d   Buchanan, Charles M ^b  

^a GOETHE UNIVERSITY   (Germany)

^b EASTMAN CHEMICAL COMPANY   (United States)

^c EAST TENNESSEE STATE UNIVERSITY   (United States)

^d VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

cyclodextrin; Bioavailability; Drug complexation; Drug solubility; Glyburide

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; GLIBENCLAMIDE; HYDROXYBUTENYL BETA CYCLODEXTRIN; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; DRUG DETERMINATION; DRUG INDICATION; DRUG SOLUBILITY; NON INSULIN DEPENDENT DIABETES MELLITUS;

BETA-CYCLODEXTRINS; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIFFERENTIAL THERMAL ANALYSIS; GASTRIC JUICE; GELATIN; GLYBURIDE; HYDROGEN-ION CONCENTRATION; PHARMACEUTICAL PREPARATIONS; PHYSICOCHEMICAL PROCESSES; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 58149216403     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.01.0004     Document Type: Article

References (45)

1. Amidon GL et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
2. Nathanson MH et al. Stimulation of bile duct epithelial secretion by glybenclamide in normal and cholestatic rat liver. J Clin Invest 1998; 101; 2665-2676.
3. Leuner C, Dressman J. Irnproving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000; 50: 47-60.
4. Malmsten M. Surfactants and Polymers in Drug Delivery. New York: Marcel Dekker, Inc., 2002.
5. Buchanan CM et al. Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations. J Pharm Sci 2007; 96: 3100-3116.
6. Buchanan CM et al. Synthesis and characterization of watersoluble hydroxybutenyl cyclomaltooligosaccharides (cyclodextrins). Carbohydr Res 2002; 337: 493-507.
7. Loftsson T. Cyclodextrins and the biopharmaceutics classification system of drugs. J Inclusion Phenom Macrocyclic Chem 2002; 44: 63-67.
8. Loftsson T, O'Fee R. Cyclodextrins in solid dosage forms. Business Briefing: Pharmatech 2003; 176-180.
9. Wempe MF et al. Pharmacokinetics of letrozole in male and female rats: influence of complexation with hydroxybutenyl-betacyclodextrin. J Pharm Pharmacol 2007; 59: 795-802.
10. Uekama K. Recent aspects of pharmaceutical application of cyclodextrins. J Inclusion Phenom Macrocyclic Chem 2002: 44: 3-7.
11. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007; 59: 645-666.
12. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007; 329: 1-11.
13. Barrow PC et al. The reproductive and developmental toxicity profile of beta-cyclodextrin in rodents. Reprod Toxicol 1995; 9: 389-398.
14. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. 3. Toxicological issues and safety evaluation. J Pharm Sci 1997; 86: 147-162.
15. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 1996; 85: 1142-1169.
16. Saenger W. Cyclodextrin inclusion-compounds in research and industry. Angew Chemie Int Ed Engl 1980; 19: 344-362.
17. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev 1998; 98: 1743-1754.
18. Li J et al. Drug carrier systems based on water-soluble cationic beta-cyclodextrin polymers. Int J Pharm 2004; 278: 329-342.
19. Buchanan CM et al. Solubilization and dissolution of tamoxifen-hydroxybutenyl cyclodextrin complexes. J Pharm Sci 2006; 95: 2246-2255.
20. Buchanan CM et al. Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-betacyclodextrin formulations. J Pharm Sci 2007; 96: 644-660.
21. Buchanan CM et al. Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-betacyclodextrin formulations. Biomacromolecules 2008; 9: 305-313.
22. Wempe MF et al. Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta- cyclodextrin. Int J Pharm 2008; 346: 25-37.
23. Kasim NA et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; 1: 85-96.
24. Lindenberg M et al. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004; 58: 265-278.
25. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22: 11-23.
26. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Geneva: World Health Organization, 1999.
27. World Health Organization. Fact sheet No 312. Diabetes. Geneva: World Health Organization. 2006.
28. Merck & Co. Inc. The Merck Index. Rahway, NJ: Merck & Co.. Inc., 2006.
29. Avdeef A. Solubility of sparingly-soluble ionizable drugs. Adv Drug Deliv Rev 2007; 59: 568-590.
30. Moffat, AC et al. eds. Clarkes Analysis of Drugs and Poisons. 3rd edn. London: Pharmaceutical Press. 2004.
31. Pearson JG. Pharmacokinetics of glyburide. Am J Med 1985; 79:67-71.
32. Savolainen J et al. Co-administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms. Pharm Res 1998: 15: 1696-1701.
33. Wei H et al. Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption. Eur J Pharm Biopharm 2008; 69: 1046-1056.
34. Marques M. Dissolution media simulating fasted and fed states. Dissolution Technol 2004; 11: 16
35. Klein, S. Biorelevant dissolution test methods for modified release dosage forms (dissertation Goethe University, Frankfurt. Germany). Auchen, Germany: Shaker-Verlag, 2005.
36. Nicolaides E et al. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm Res 1999; 16: 1876-1882.
37. Zoeller T, Klein S. Simplified biorelevant media for screening dissolution performance of poorly soluble drugs. Dissolution Technol 2007; 14: 8-13.
38. US Food and Drug Administration. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. 2000.
39. World Health Organization. Proposal to waive in vivo bioequivalence requirements for the WHO model list of essential medicines immediate release, solid oral dosage forms. Working document QAS/04.109/Rev. 1. Geneva: World Health Organization, 2005.
40. Russel TL et al. Upper gastrointestinal pH in seventy-nine healthy, elderly, North-American men and women. Pharm Res 1993; 10: 1987-1996.
41. Chen TM et al. Evaluation of a method for high throughput solubility determination using a multi-wavelength UV plate reader. Comb Chem High Throughput Screen 2002: 5: 575-581.
42. Stippler E. Biorelevant dissolution test methods to assess bioequivalence of drug products (dissertation Goethe University, Frankfurt, Germany). Auchen, Germany: Shaker-Verlag. 2004.
43. Ozturk SS et al. Dissolution of ionisable drugs in buffered and unbuffered solutions. Pharm Res 1988; 5: 272-282.
44. Babu RJ, Pandit JK. Enhancement of dissolution rate and hypoglycemic activity of glibenclamide with beta-cyclodextrin. STP Pharma Sci 1995; 5: 196-201.
45. Loftsson T et al. Role of cyclodextrins in improving oral drug delivery. Am J Drug Deliv 2004; 2: 261-275.